(Q54708579)

3 June 2018

title

Guidelines for the management of diffuse large B-cell lymphoma. (English)

1 reference

3 June 2018

author

Sally Barrington

3

1 reference

3 June 2018

Kim Linton

5

1 reference

3 June 2018

British Committee for Standards in Haematology

11

object named as

British Committee for Standards in Haematology

1 reference

3 June 2018

Sridhar Chaganti

1

1 reference

3 June 2018

Tim Illidge

2

1 reference

3 June 2018

Pam Mckay

4

1 reference

3 June 2018

Kate Cwynarski

6

1 reference

3 June 2018

Andrew McMillan

7

1 reference

3 June 2018

Andy Davies

8

1 reference

3 June 2018

Simon Stern

9

1 reference

3 June 2018

Karl Peggs

10

1 reference

3 June 2018

language of work or name

English

0 references

publication date

16 May 2016

1 reference

3 June 2018

British Journal of Haematology

published in

1 reference

3 June 2018

volume

174

1 reference

3 June 2018

issue

1

1 reference

3 June 2018

page(s)

43-56

1 reference

3 June 2018

FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis

cites work

1 reference

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

21 January 2018

1 reference

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

21 January 2018

1 reference

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

21 January 2018

1 reference

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

21 January 2018

1 reference

Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma

21 January 2018

1 reference

In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.

21 January 2018

1 reference

Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.

21 January 2018

1 reference

Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome.

21 January 2018

1 reference

British HIV Association guidelines for HIV-associated malignancies 2014.

21 January 2018

1 reference

The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement.

21 January 2018

1 reference

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation

21 January 2018

1 reference

Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma.

21 January 2018

1 reference

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

21 January 2018

1 reference

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

21 January 2018

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

21 January 2018

1 reference

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy

21 January 2018

1 reference

HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era.

21 January 2018

1 reference

Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients

21 January 2018

1 reference

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

21 January 2018

1 reference

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

21 January 2018

1 reference

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study

21 January 2018

1 reference

Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies

21 January 2018

1 reference

Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era.

21 January 2018

1 reference

De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.

21 January 2018

1 reference

Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.

21 January 2018

1 reference

The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

21 January 2018

1 reference

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma

21 January 2018

1 reference

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

21 January 2018

1 reference

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients

21 January 2018

1 reference

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma

21 January 2018

1 reference

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.

21 January 2018

1 reference

The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.

21 January 2018

1 reference

Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

21 January 2018

1 reference

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

21 January 2018

1 reference

Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group

21 January 2018

1 reference

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

21 January 2018

1 reference

Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma

21 January 2018

1 reference

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

21 January 2018

1 reference

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement.

21 January 2018

1 reference

HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL).

21 January 2018

1 reference

Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome

21 January 2018

1 reference

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

21 January 2018

1 reference

Stromal gene signatures in large-B-cell lymphomas

21 January 2018

1 reference

B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.

21 January 2018

1 reference

The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma.

21 January 2018

1 reference

Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

21 January 2018

1 reference

Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi

21 January 2018

1 reference

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

21 January 2018

1 reference

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

21 January 2018

1 reference

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry

21 January 2018

1 reference

Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort

21 January 2018

1 reference

Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment

21 January 2018

1 reference

Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA.

21 January 2018

1 reference

Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate

21 January 2018

1 reference

MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations

21 January 2018

1 reference

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

21 January 2018

1 reference

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

21 January 2018

1 reference

How I treat elderly patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

21 January 2018

1 reference

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

21 January 2018

1 reference

Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy

21 January 2018

1 reference

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

21 January 2018

1 reference

On the added value of baseline FDG-PET in malignant lymphoma

21 January 2018

1 reference

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

21 January 2018

1 reference

EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer

21 January 2018

1 reference

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

21 January 2018

1 reference

Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience

21 January 2018

1 reference

Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.

21 January 2018

1 reference

Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience.

21 January 2018

1 reference

Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma

21 January 2018

1 reference

Epidemiology of hematological malignancies

21 January 2018

1 reference

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

21 January 2018

1 reference

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

21 January 2018

1 reference

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

21 January 2018

1 reference

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

21 January 2018

1 reference

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

21 January 2018

1 reference

Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency.

21 January 2018

1 reference

Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellu

21 January 2018

1 reference

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

21 January 2018

1 reference

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

21 January 2018

1 reference

Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

Molecular diagnosis of the hematologic cancers

21 January 2018

1 reference

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study.

21 January 2018

1 reference

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

21 January 2018

1 reference

High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry

21 January 2018

1 reference

Late relapse in patients with diffuse large B‐cell lymphoma

21 January 2018

1 reference

Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the

21 January 2018

1 reference

Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.

21 January 2018

1 reference

Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma

21 January 2018

1 reference

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

21 January 2018

1 reference

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.

21 January 2018

1 reference

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

21 January 2018

1 reference

Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.

21 January 2018

1 reference

Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.

21 January 2018

1 reference

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

21 January 2018

1 reference

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

21 January 2018

1 reference

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma

21 January 2018

1 reference

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial G

21 January 2018

1 reference

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.14136

1 reference

3 June 2018

1 reference

3 June 2018